Outcomes from massive paracetamol overdose: a retrospective observational study by Marks, DJB et al.
 1 
Outcomes from massive paracetamol overdose: a retrospective 1 
observational study 2 
Daniel J B Marks1,2, Paul I Dargan1,3, John R H Archer 1,3, Charlotte L Davies2, 3 
Alison M Dines1, David M Wood1,3, Shaun L Greene4 4 
 5 
1Department of Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust 6 
and King’s Health Partners, London, UK, 2Department of Clinical Pharmacology, 7 
University College London, London UK, 3Faculty of Life Sciences and Medicine, 8 
King’s College London, London, UK, 4Austin Toxicology Service and Victorian 9 
Poisons Information Centre, Austin Hospital, Victoria, Australia 10 
 11 
Submitting author Dr Daniel J B Marks, Centre for Molecular Medicine, 12 
University College London, UK; E-mail: d.marks@ucl.ac.uk 13 
 14 
Correspondence Dr Shaun L Greene, Austin Toxicology Service and Victorian 15 
Poisons Information Centre, Austin Hospital, Victoria, Australia; E-mail: 16 
shaun.greene@austin.org.au 17 
 18 
Principal investigator Dr Shaun L Greene 19 
Running head Massive paracetamol overdose 20 
Keywords acetylcysteine, coagulopathy, hepatotoxicity, paracetamol, overdose 21 
Word count 3,217 22 
Tables 4; Figures 4 23 
24 
 2 
STRUCTURED SUMMARY 25 
AIM 26 
Treatment of paracetamol (acetaminophen) overdose with acetylcysteine is 27 
standardised, with dose determined only by patient weight. The validity of this 28 
approach for massive overdoses has been questioned. We systematically 29 
compared outcomes in massive and non-massive overdoses, to guide whether 30 
alternative treatment strategies should be considered, and whether the ratio 31 
between measured timed paracetamol concentrations (APAPpl) and treatment 32 
nomogram thresholds at those time points (APAPt) provides a useful assessment 33 
tool.  34 
METHODS  35 
Retrospective observational study of all patients (n=545) between 2005-2013 36 
admitted to a tertiary care toxicology service with acute non-staggered 37 
paracetamol overdose. Massive overdoses were defined as extrapolated 4-hour 38 
plasma paracetamol concentrations >250mg/L, or reported ingestions ≥30g. 39 
Outcomes (liver injury, coagulopathy and kidney injury) were assessed in 40 
relation to reported dose and APAPpl:APAPt ratio (based on a treatment line 41 
through 100mg/L at 4 hours), and time to acetylcysteine.  42 
RESULTS  43 
Ingestions of ≥30g paracetamol correlated with higher peak serum 44 
aminotransferase (r=0.212, P<0.0001) and creatinine (r=0.138, P=0.002) 45 
concentrations. Acute liver injury, hepatotoxicity and coagulopathy were more 46 
frequent with APAPpl:APAPt ≥3 with odds ratios (OR) and 95% confidence 47 
intervals (CI) of 9.19 (5.04-16.68), 35.95 (8.80-158.1) and 8.34 (4.43-15.84), 48 
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respectively (P<0.0001). Heightened risk persisted in patients receiving 49 
acetylcysteine within 8 hours of overdose.  50 
CONCLUSION  51 
Patients presenting following massive paracetamol overdose are at higher risk of 52 
organ injury, even when acetylcysteine is administered early. Enhanced 53 
therapeutic strategies should be considered in those who have an APAPpl:APAPt 54 
≥3. Novel biomarkers of incipient liver injury and abbreviated acetylcysteine 55 
regimens require validation in this patient cohort.  56 
 57 
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 58 
 Acetylcysteine protocols in paracetamol overdose were initially 59 
developed empirically, with subsequent validation using pharmacokinetic 60 
studies of non-toxic doses in healthy individuals. 61 
 It is unclear whether these modelling assumptions are robust in massive 62 
overdoses. 63 
 Case reports suggest that such patients may have worse outcomes, and 64 
biochemical data hint at the need for supplemental acetylcysteine. 65 
 66 
WHAT THIS STUDY ADDS 67 
 Patients with an APAPpl:APAPt ≥3 (based on a treatment line through 68 
100mg/L at 4 hours) have higher rates of organ injury. 69 
 Excess risk persists even with acetylcysteine administration within 8 70 
hours of overdose. 71 
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 Patients with massive overdoses may benefit from higher or protracted 72 
doses of acetylcysteine, or approaches to enhance gastrointestinal drug 73 
elimination. 74 
 75 
TABLE OF LINKS 76 
LIGANDS 
paracetamol 
This Table lists key ligands in this article that are hyperlinked to corresponding 
entries in http://www.guidetopharmacology.org, the common portal for data 




Introduction  79 
Paracetamol overdose remains the commonest drug overdose, and cause of 80 
acute liver failure, in Europe, Australia and North America [2, 3] Intravenous 81 
acetylcysteine is the mainstay of treatment and an effective antidote if used early 82 
in the course of poisoning [3, 4]. The decision to treat acute, non-staggered, 83 
paracetamol overdose is principally based on measured plasma paracetamol 84 
concentrations, taken at least 4 hours after ingestion [3]. International guidelines 85 
differ in their recommendations as to threshold paracetamol concentrations for 86 
treatment on nomograms, but once these have been exceeded acetylcysteine 87 
dosing regimens are very similar throughout the world [5]. The dose of 88 
acetylcysteine is determined only by patient weight, and does not vary according 89 
to other factors including the dose of paracetamol taken, plasma paracetamol 90 
concentration, time to presentation, and/or co-ingestion of other drugs. 91 
 Acetylcysteine regimens have never been subject to definitive dose-92 
ranging studies in humans, nor have different regimens been compared in 93 
randomised controlled trials sufficiently powered to inform on the optimal 94 
strategy for preventing hepatotoxicity. As a result, current guidelines still 95 
advocate treatment principally based on the dose calculated in the 1970s for the 96 
initial studies of acetylcysteine in paracetamol toxicity [4]. At this time, there 97 
were few data to inform on appropriate dosing, and much of the initial work was 98 
empirical. It had, however, been established that hepatic and renal toxicity were 99 
mediated through formation of N-acetyl-p-benzoquinone imine (NAPQI), once 100 
paracetamol conjugation through glucuronidation and sulphation had been 101 
saturated [6]. NAPQI can be detoxified to cysteine and mercapturate conjugates 102 
by glutathione, with organ injury resulting once stores of the latter become 103 
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deplete [7]. Consequently, pharmacokinetic studies were performed in healthy 104 
individuals to determine the level of glutathione depletion over a range of 105 
paracetamol concentrations, and a dose of acetylcysteine selected that would 106 
match this on a stoichiometric basis [5, 7].  107 
Whilst this standard treatment regimen has proven extremely successful, 108 
the “one size fits all” approach has been criticized [5, 8, 9]. In particular, it is not 109 
clear whether the modelling assumptions underlying the initial acetylcysteine 110 
dose calculations hold true with very large overdoses, and whether therapy 111 
could be better tailored to individual cases in these situations [10, 11]. Several 112 
case reports, and one recent observational study, highlight adverse outcomes in 113 
patients with massive paracetamol overdoses despite early acetylcysteine [12-114 
16]. Such patients have higher cysteine and mercapturate to glucuronide 115 
conjugate ratios, implying increased proportions of paracetamol undergoing 116 
conversion to NAPQI and consistent with the need for supplemental 117 
acetylcysteine beyond that suggested by the original models [6]. The aims of this 118 
study were to evaluate the development of organ injury in massive overdoses in 119 
a systematic manner, compare this to non-massive ingestions, and assess 120 
whether reported ingested dose or the ratio of the measured plasma 121 
paracetamol concentration (APAPpl) to the corresponding treatment nomogram 122 
paracetamol concentration threshold at that time (APAPt) provided superior 123 
prediction of outcome. We assessed all patients presenting to a specialist 124 
toxicology service with acute paracetamol overdose meeting criteria for 125 
treatment with acetylcysteine, and determined outcomes for those taking 126 




Patients and clinical data 130 
Clinical data on all patients presenting to our large inner-city hospital with 131 
toxicology-related problems are prospectively entered into a purpose-designed 132 
clinical database, with follow-up to the end of the acute inpatient admission 133 
episode [17]. Data were extracted for all individuals who had taken an acute, 134 
single (non-staggered) overdose of paracetamol in whom the time of ingestion 135 
was recorded, and who received treatment with acetylcysteine, between May 136 
2005 and May 2013.  There are no universally agreed criteria of what constitutes 137 
a massive paracetamol overdose; we therefore defined this pragmatically as an 138 
extrapolated 4-hour plasma paracetamol concentration >250mg/L (2.5-fold the 139 
current UK threshold requiring treatment with acetylcysteine), or (where 140 
plasma paracetamol concentrations were not available) if a patient reported 141 
ingestion of ≥30g paracetamol. Caldicott and Ethical Approval are in place for the 142 
database; data for this study were analysed anonymously and therefore no 143 
further ethical approval was required. This manuscript is written in compliance 144 
with STROBE guidelines. 145 
The following information was extracted from the database: basic 146 
demographic data; time of presentation to the emergency department; reported 147 
quantity and time of paracetamol ingested; plasma paracetamol concentration 148 
(APAPpl) and time (t) this blood test was performed relative to exposure; time to 149 
initiation of acetylcysteine; and peak serum aminotransferase concentration, 150 
international normalized ratio (INR) and serum creatinine occurring on 151 
admission or during the course of treatment. Calculated 4-hour plasma 152 
paracetamol concentrations were back-extrapolated from measured values using 153 
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the formula used in previous studies: APAPpl/2e-(0.693/4)t [18]. We also calculated 154 
the ratio between APAPpl and the threshold concentration at that time point on 155 
the treatment nomogram (based on a line through 100mg/L at 4 hours) above 156 
which acetylcysteine would be administered (APAPt).  157 
 158 
Treatment regimens during study period  159 
In the UK prior to 2012, single (non-staggered) paracetamol overdoses were 160 
treated with acetylcysteine if measured plasma paracetamol concentrations 161 
were above a nomogram line starting at 200mg/L at 4 hours if deemed standard 162 
risk, or 100mg/L at 4 hours if high risk (for example, patients with chronic 163 
alcohol misuse, medical conditions associated with glutathione depletion, and/or 164 
taking cytochrome P450-2E1 inducing medication). The standard acetylcysteine 165 
protocol was 150mg/kg over 15 minutes, followed by 50mg/kg over 4 hours, 166 
and finally 100mg/kg over 16 hours. From 2012, UK guidelines changed such 167 
that everyone was treated according to the 100mg/L at 4 hours nomogram 168 
threshold line, with the duration of the first dose of acetylcysteine extended to 1 169 
hour [19]. With both of these regimens, after completion of the third infusion, 170 
renal function, liver function and coagulation parameters are rechecked, and a 171 
further 16 hour acetylcysteine infusion instituted in the event of any significant 172 
derangement [20]. 173 
 174 
Assessment of organ injury  175 
There are a number of different working definitions for liver injury based on 176 
rises in serum alanine or aspartate aminotransferase concentrations, and data 177 
for all of the following were considered: 1. paracetamol-related liver injury, 178 
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defined by a rise ≥2-fold the upper limit of normal (ULN; the threshold above 179 
which UK guidelines recommend extending the acetylcysteine course) [8]; 2. 180 
drug-induced acute liver injury, defined as ≥3-fold ULN [16, 21]; and 3. 181 
paracetamol-related hepatotoxicity, with aminotransferase concentrations 182 
>1,000IU/L [4, 15, 22]. Coagulopathy was defined as an INR rising above 1.3 (the 183 
threshold that would prompt extension of acetylcysteine therapy) [23], and 184 
significant acute kidney injury as a serum creatinine >150μmol/L (in the absence 185 
of pre-existing chronic kidney disease) [24]. In addition, current UK guidelines 186 
advocate consideration for liver transplantation in paracetamol overdoses with 187 
an INR >6.5 or serum creatinine >300μmol/L [23].  188 
 189 
Statistical analysis 190 
Data are expressed as median (interquartile range), unless otherwise stated, and 191 
were analysed using GraphPad Prism (version 7.0; GraphPad Software, CA, 192 
2016). All eligible patients within the specified time frame were included in the 193 
study, and no formal power calculation was performed. Continuous variables 194 
were compared using the Mann-Whitney U-test, correlation by Spearman rank 195 
coefficient, and event frequencies by Fisher’s exact test. A P value ≤0.05 was 196 
considered significant. Analyses did not impute missing data. 197 
 198 
Results 199 
Patient and overdose characteristics 200 
A total of 545 patients fulfilled the inclusion criteria. Median age was 31 (22-43) 201 
years, and 341 (62.6%) patients were female. Median time from overdose to 202 
presentation was 3h25min (1h44min-6h47min). Plasma paracetamol 203 
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concentrations were available in 529 (97%) patients; in four individuals the 204 
samples had haemolysed and were not repeated, and in twelve individuals they 205 
were not performed. Median plasma paracetamol concentration was 119mg/L 206 
(66-182), and time from exposure to measurement was 5h47min (4h36min-207 
9h5min). The median extrapolated 4-hour concentration was 190.0 (126.8-208 
273.5) mg/L. 209 
 210 
Reported ingested dose of paracetamol 211 
The reported ingested dose was recorded in 520 (95.4%) cases, with a median of 212 
16 (12.5-25) grams. One hundred and four patients (20.0%) took a dose ≥30g,  213 
and the maximum ingested dose was 141g. Reported ingested doses correlated 214 
with extrapolated 4-hour plasma concentrations (r=0.367, P<0.0001; Figure 1a).  215 
 216 
APAPpl:APAPt ratios 217 
Ratios were calculated in 527 (96.7%) patients; in the remainder this was not 218 
possible either due to lack of a measured plasma paracetamol concentration 219 
(n=4) or due to late presentation beyond the time limits of treatment 220 
nomograms (n=14). The median ratio was 1.94 (1.30-2.77). This measure 221 
correlated strongly with 4-hour extrapolated plasma concentrations (r=0.999, 222 
P<0.0001), and moderately with reported dose (r=0.368, P<0.0001; Figure 1b).  223 
 224 
Prevalence of organ injury 225 
Peak serum aminotransferase concentrations, INR and creatinine results were 226 
available in 538, 540 and 542 patients, respectively. One hundred and seventeen 227 
(21.5%) patients had peak serum aminotransferase concentrations >2-fold ULN; 228 
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69 (12.8%) >3-fold ULN; and 20 (3.7%) >1,000 IU/L. Forty-nine (9.1%) had a 229 
peak INR >1.3; and 2 (3.7%) >6.5. Nine (1.7%) had significant acute kidney 230 
injury with a creatinine >150μmol/L, and 4 (0.7%) >300μmol/L. Fifty-three 231 
(9.7%) patients received additional acetylcysteine beyond the standard regimen. 232 
All patients recovered from the acute episode of poisoning, except for one 233 
individual who presented 13h8min after reported ingestion of 24g paracetamol 234 
and ethanol, and developed chronic renal impairment requiring long-term renal 235 
replacement therapy. This patient also had acute liver failure with a serum 236 
aminotransferase concentration of 8,509 IU/L and INR of 3.32, although hepatic 237 
function subsequently recovered and was normal at the time of hospital 238 
discharge. No patients died as a result of the acute episode of poisoning. 239 
 240 
Relationship between estimates of overdose and development of organ 241 
injury 242 
Patient demographics described by nomogram group (according to extrapolated 243 
4-hour plasma paracetamol concentrations) are shown in Table 1. Correlations 244 
between reported ingested dose, 4-hour extrapolated plasma paracetamol 245 
concentrations, APAPpl:APAPt, and the various outcome measures were assessed 246 
(Table 2). Sensitivities, specificities, positive predictive values, and odds ratios 247 
for different APAPpl:APAPt thresholds for identifying serum aminotransferase 248 
rises >2-fold ULN (promoting extended acetylcysteine infusion) are reported in 249 
Table 3. 250 
 251 
Relationship to reported ingested dose of paracetamol 252 
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Reported ingested dose correlated with peak serum aminotransferase 253 
concentrations (r=0.212, P<0.0001; Figure 2a) and creatinine (r=0.138, P=0.002; 254 
Figure 2b), but not INR (r=0.034, p=ns; Figure 2c). Median peak serum 255 
aminotransferase concentration was 23IU/L (16.75-39.25) in patients reporting 256 
overdoses under 30g, and 29IU/L (22-73) in those who had taken ≥30g 257 
(P=0.001). Reported dose did not reliably differentiate the different grades of 258 
liver injury (Figure 2d). Median INR was 1.1 in both patients taking ≥30g 259 
paracetamol and also those reporting non-massive overdoses (IQR 1.02-1.18 and 260 
1.03-1.19, respectively). Median serum creatinine was 65μmol/L (57-75) in 261 
patients reporting ingestions <30g and 72.5μmol/L (63.25-82.75) in those who 262 
reported ingestion of ≥30g (P<0.0001), but there was no difference in the 263 
frequency of creatinine rises over 150μmol/L (<30g, n=5; ≥30g, n=3) or 264 
300μmol/L (<30g, n=1; ≥30g, n=2) between these groups. 265 
 266 
Relationship to APAPpl:APAPt 267 
APAPpl:APAPt ratio correlated with peak serum aminotransferase concentration 268 
(r=0.286, P<0.0001; Figure 3a), INR (r=0.314, P<0.0001; Figure 3b) and 269 
creatinine concentration (r=0.090, P=0.04; Figure 3c). There were associations 270 
between increasing APAPpl:APAPt and liver injury (Figure 4a-c), coagulopathy 271 
(Figure 4d) and acute kidney injury. A ratio ≥3 was associated with an OR of 7.15 272 
(4.20-12.06; P<0.0001) for peak serum aminotransferase concentrations >2-fold 273 
ULN; 9.19 (5.04-16.68; P<0.0001) for acute liver injury; 35.95 (8.80-158.1; 274 
P<0.0001) for hepatotoxicity; 8.34 (4.43-15.85; P<0.0001) for coagulopathy; and 275 
4.69 (1.38-15.44; P=0.03) for acute kidney injury.  276 
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 Correspondingly, values for APAPpl:APAPt ratios ≥6 were 13.93 (6.24-277 
31.79; P<0.0001) for aminotransferase rises >2-fold ULN; 15.94 (6.97-35.32; 278 
P<0.0001) for acute liver injury; 44.64 (15.0-121.5; P<0.0001) for 279 
hepatotoxicity; 13.59 (5.84-32.33; P<0.0001) for coagulopathy; and 10.65 (2.75-280 
39.12; P=0.008) for acute kidney injury.  281 
 282 
Time to acetylcysteine and outcomes 283 
Median time to acetylcysteine was 8h30min (6h24min-12h36) in male patients 284 
and 7h42min (6h0min-10h18min) in female patients (P=0.03). Time to 285 
treatment correlated with serum aminotransferase concentration (r=0.168 286 
P=0.0002), INR (r=0.153, P=0.0006) and serum creatinine (r=0.087, P=0.05).  287 
We subsequently restricted analyses to the 248 patients who received 288 
acetylcysteine within 8 hours of reported paracetamol ingestion (Table 4).  The 289 
association between reported ingested dose and serum aminotransferase 290 
concentration persisted (r=0.153, P=0.02), as did those between APAPpl:APAPt 291 
and serum aminotransferases or INR. An APAPpl:APAPt ≥3 remained predictive 292 
of organ injury with an OR of 5.25 (1.98-13.13; P=0.002) for aminotransferase 293 
rise >2-fold ULN; 4.70 (1.66-14.48; P=0.02) for acute liver injury; ∞ (3.56-∞; 294 
P=0.01) for hepatotoxicity; and 5.21 (1.60-18.3; P=0.02) for coagulopathy.   295 
By comparison, in patients who received acetylcysteine later than 8 hours 296 
from reported ingestion, APAPpl:APAPt ≥3 had an OR of 8.61 (3.90-18.23; 297 
P<0.0001) for aminotransferase rises >2-fold ULN; 11.38 (4.91-25.36; P<0.0001) 298 
for acute liver injury; 18.88 (4.73-84.67; P<0.0001) for hepatotoxicity; and 9.46 299 




Although the current regimen of acetylcysteine for treating paracetamol 303 
overdose has been extremely successful, the continued use of a standard 304 
protocol for every case has been questioned [5, 8, 9]. In particular, it has been 305 
suggested that patients who have taken very large overdoses may require higher 306 
doses of acetylcysteine, or protracted infusions. Intravenous doses up to 307 
980mg/kg acetylcysteine over 48 hours have previously been used safely [25], 308 
notwithstanding evidence from one animal model that suggested prolonged 309 
therapy might delay recovery from hepatotoxicity [26]. It is known that NAPQI 310 
generation rises with increasing paracetamol dose, and also that hepatic injury 311 
prolongs paracetamol half-life. Furthermore, there are several case reports, and 312 
one observational study, of patients developing hepatotoxicity despite receiving 313 
acetylcysteine within 8 hours of reported overdose [12-16].  314 
Our study systematically assessed outcomes of massive paracetamol 315 
overdose. Key findings were that, despite receiving standard therapy with 316 
acetylcysteine, patients with massive overdoses were more likely to develop 317 
significant liver and kidney injury, and coagulopathy. APAPpl:APAPt ratio was a  318 
better predictor of organ toxicity than the reported dose ingested. Although 319 
overall correlations with outcomes were modest in magnitude, and differences in 320 
medians (while statistically significant) were of limited clinical relevance, this 321 
did provide a tool for distinguishing higher and lower risk groups. This persisted 322 
even when acetylcysteine was administered within 8 hours of reported 323 
ingestion, demonstrating that while time to treatment was a strong predictor of 324 
organ injury it was not the sole determining factor in early presenting poisoning. 325 
These findings validate and extend, in an independent cohort, those recently 326 
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published by a specialist toxicology unit in Edinburgh [16]. The case features in 327 
our patients were broadly similar, except that liver injury and hepatotoxicity 328 
were more frequent in the highest concentration subgroups in our study; this 329 
may relate to the higher measured paracetamol concentrations at the times of 330 
presentation.  331 
 The original acetylcysteine treatment regimen was constructed based on 332 
empirical considerations [4, 7]. Although effective for the majority of patients, it 333 
is not clear that the implicit assumptions necessarily hold true in massive 334 
overdose. In such patients, absorption of paracetamol may be delayed: this could 335 
be due to direct effects of paracetamol on gastric motility [27]; co-ingestion of 336 
other drugs such as opiates or anticholinergics that delay gastric emptying [28]; 337 
insufficient volume of gastric secretions to solubilize large quantities of 338 
paracetamol [29]; or formation of a pharmacological bezoar [13]. The half-life of 339 
paracetamol can progressively extend as hepatotoxicity develops, such that 340 
significant quantities of NAPQI could be generated after the 16-hour 341 
acetylcysteine infusion has finished [30]. Finally, there is evidence from animal 342 
models that paracetamol may undergo enterohepatic recirculation, with 343 
hydrolysis of non-toxic conjugates by gut flora and reabsorption of the parent 344 
drug [31]. These factors likely explain, alone or in combination, the double peaks 345 
of plasma paracetamol reported following large overdoses [13]. In some of these 346 
patients, the second peak can occur in excess of 30 hours after ingestion, and 347 
these individuals are more likely to develop hepatotoxicity despite early 348 
acetylcysteine therapy.  349 
While there has been considerable recent interest in the development of 350 
novel early biomarkers, such as miRNA-122, to further stratify those at high risk 351 
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of tissue injury and guide management, there is a possibility these might fail to 352 
identify cases if a major contributor to adverse outcomes in massive paracetamol 353 
overdose is a delay in the pharmacokinetic profile [32]. This is also relevant 354 
when considering adoption of an abbreviated acetylcysteine protocol [33], and 355 
might mandate protracted observation in people who have taken massive doses. 356 
It is important that this patient cohort is specifically considered when evaluating 357 
proposed changes to practice. 358 
There are a few limitations to the current study. Principal among these is 359 
the reliance on an accurate patient history and medical documentation at the 360 
time of clinical review, particularly as regards paracetamol dose and time of 361 
ingestion. As the database is clinical, there is a risk of misclassification since data 362 
are not validated at the time of entry, although one strength of this approach is 363 
that data entry is blinded to the study question. The correlations between 364 
reported doses, extrapolated 4-hour plasma paracetamol concentrations and 365 
APAPpl:APAPt provide some reassurance that these possess a reasonable degree 366 
of reliability, although concordance was lower than in previously reported series 367 
[34] and there were a number of outliers. These could result from errors in 368 
patient estimation of dose or calculation by the admitting physician, or by an in 369 
increase in the half-life of paracetamol as has been previously documented in 370 
patients with significant paracetamol toxicity, thus introducing inaccuracies into 371 
extrapolation of paracetamol concentrations. Secondly, blood tests for 372 
paracetamol, liver, coagulation and renal function were performed routinely 373 
during clinical practice at presentation to the Emergency Department, as well as 374 
on completion of the standard acetylcysteine regimen, and were thus not 375 
completely systematic. In the absence of more frequent testing it is possible that 376 
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in some cases peak values may have been missed. In addition, at our hospital at 377 
the time of this study, paracetamol concentrations were not repeated during or 378 
after treatment, so it is not possible to comment on alterations in plasma half-379 
life. It was also not possible to formally grade kidney injury using RIFLE/AKIN 380 
criteria, due to the lack of baseline blood tests and limited longitudinal follow-up 381 
in this patient cohort. Third, prior to 2012, the acetylcysteine protocol required 382 
calculations to be performed by both the prescribing physician, as well as the 383 
administering nurses. This process is error prone [35], and hence it is possible 384 
that some patients nominally receiving early treatment were in fact under-385 
dosed. Finally, the assumptions underlying extrapolation of 4-hour paracetamol 386 
concentrations may break down if paracetamol metabolism changes in a non-387 
liner fashion or becomes saturated at very high doses, or should a double peak 388 
phenomenon exist widely.   389 
These findings are clinically important, as they suggest that under current 390 
protocols patients taking massive paracetamol overdoses may be undertreated, 391 
and that either an increase in the dose intensity and/or duration of 392 
acetylcysteine therapy could be beneficial. A high APAPpl:APAPt ratio is 393 
associated with increased risk and therefore further consideration should be 394 
given to alternative acetylcysteine treatment strategies in these patients. Risks of 395 
organ injury rose with an APAPpl:APAPt  (based on a treatment line through 396 
100mg/L at 4 hours) ≥3, and a ratio ≥6 was strongly predictive. Based on 397 
analysis of the sensitivities and positive predictive values of different threshold 398 
ratios, we believe on balance that the former cut-off should be used to define a 399 
higher risk group. The optimum strategy is not clear at present, and would 400 
require a more detailed understanding of the mechanisms responsible for the 401 
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excess in organ injury despite early acetylcysteine. This could be informed by 402 
performing serial plasma paracetamol measurements in at-risk individuals to 403 
determine whether this relates to delayed absorption, second peaks or 404 
prolonged half-life. In the event of a significant contribution from the former, or 405 
substantial enterohepatic recirculation of the parent drug, there may also be a 406 
role for multiple doses of activated charcoal to augment gastrointestinal 407 
elimination. Novel biomarkers of liver injury, and abbreviated treatment 408 
protocols, should be specifically validated in this patient cohort.  409 
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FIGURE LEGENDS 545 
Figure 1 Correlations between reported dose of paracetamol and ingested and 546 
a) extrapolated 4-hour plasma paracetamol concentrations and b) APAPpl:APAPt.  547 
 548 
Figure 2 Relationship between reported dose of paracetamol ingested and a) 549 
serum aminotransferase concentration, b) INR and c) serum creatinine. d) 550 
Cumulative frequency of different grades of liver injury with reported dose. 551 
 552 
Figure 3 Relationship between APAPpl:APAPt and a) serum aminotransferase 553 
concentration, b) INR and c) serum creatinine. 554 
 555 
Figure 4 Percentage of patients in each APAPpl:APAPt group with a) no liver 556 
injury (serum aminotransferase concentrations <50IU/L), b) acute liver injury, 557 
c) hepatoxicity and d) coagulopathy.  558 
 559 
